William Blair analyst Margaret Kaczor has maintained their bullish stance on GKOS stock, giving a Buy rating on April 29.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Margaret Kaczor has given her Buy rating due to a combination of factors that highlight Glaukos’s promising outlook. The company’s first-quarter sales exceeded expectations, primarily driven by strong performance in iDose and international glaucoma sales. Despite some challenges, such as the local coverage determination affecting the core MIGS franchise, the management’s decision to maintain full-year revenue guidance reflects confidence in their strategic adjustments.
Furthermore, Kaczor points to several encouraging indicators, including positive month-to-month trends for iDose, increased expectations for this product, and progress in their product pipeline with minimal tariff impact. These factors, coupled with Glaukos’s efforts to meet reimbursement and commercial milestones, suggest a transformative period ahead. The recent stock pullback presents an opportunity for investors, as the company is poised for sequential growth through 2025, making it an attractive investment at its current valuation.